EUVIMEDEUVIMED entdecken
MetaanalyseOpen Access · CC BY 4.0

The shared genetic architecture of the TDP‐43 spectrum: Bridging clinical FTLD and neuropathological endophenotypes

Maulikkumar Patel iD, Pawan Kumar, Daniel Western, Matthew Johnson, Menghan Liu, John Budde, Carlos Cruchaga, Cyril Pottier iD

Alzheimer's & Dementia · 2026-11 · 22 (11)

DOI: 10.1002/alz.71943 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Alzheimer's & Dementia, online erschienen am 04.11.2026. Verfasst von Maulikkumar Patel und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri, USA. Hauptthemen laut MEDLINE: TDP-43 Proteinopathies, DNA-Binding Proteins, Frontotemporal Lobar Degeneration, Endophenotypes. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Association for Frontotemporal Degeneration.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION TAR DNA‐binding protein 43 (TDP‐43) proteinopathies encompass a spectrum of conditions including frontotemporal lobar degeneration with TDP‐43 inclusions (FTLD‐TDP), limbic‐predominant age‐related TDP‐43 encephalopathy (LATE‐NC), and hippocampal sclerosis (HS). FTLD‐TDP is further classified into several pathological subtypes (A, B, C, D, and E), which differ in the distribution and morphology of TDP‐43 inclusions. Clinical and neuropathological variability across FTLD, FTLD‐TDP, LATE‐NC, and HS has hindered the translatability of genetic discoveries between clinical and pathological disease categories. By leveraging their genetic convergence, we aimed to refine effect size estimates and uncover variants that influence the TDP‐43 spectrum. METHODS We conducted an inverse variance weighted fixed‐effects meta‐analysis using METAL, combining neuropathological datasets (FTLD‐TDP subtypes: A [ N cases = 193], B [ N cases = 288], C [ N cases = 467], and controls [ N controls = 3153]), HS ( N cases = 751; N controls = 6413), or LATE‐NC ( N cases = 1325; N controls = 1787). Additionally, we performed a random‐effects meta‐analysis that included clinically diagnosed FTLD ( N cases = 4685; N controls = 15,308) and neuropathological datasets. Moreover, we performed colocalization, fine‐mapping, and functional annotation analyses. RESULTS Three loci reached genome‐wide significance. The GRN (rs5848) and TMEM106B (rs3807865) loci were associated with FTLD‐TDP (A and B), LATE‐NC, and HS. Colocalization and fine‐mapping analyses supported genetic signals at GRN and TMEM106B loci, while functional annotation suggested that rs3807865 and rs3807866 influence regulatory activity and TMEM106B expression in glial cells. MAPT demonstrated association across all combinations of TDP‐43 proteinopathies (except FTLD‐TDP B and C) and clinical FTLD, specifically the H1c haplotype. DISCUSSION Our results extend the known role of GRN and TMEM106B beyond FTLD‐TDP subtype A, while MAPT involvement suggests a role beyond traditional tauopathies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TDP-43 ProteinopathiesDNA-Binding ProteinsFrontotemporal Lobar DegenerationEndophenotypesHumansProgranulinsHippocampal SclerosisMembrane ProteinsBrainNerve Tissue Proteins

Stichwörter der Autor:innen

GRNMAPTTAR DNA‐binding protein 43TMEM106Bfrontotemporal lobar degenerationgenome‐wide association studyhippocampal sclerosislimbic‐predominant age‐related TAR DNA‐binding protein 43 encephalopathymeta‐analyses

Substanzen

DNA-Binding ProteinsTMEM106B protein, humanProgranulinsTARDBP protein, humanMembrane ProteinsGRN protein, humanNerve Tissue Proteins

Autor:innen und Institutionen

  • Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Neurogenomics and Informatics Center, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Department of Neurology, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Knight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, Missouri, USA.

ORCID-Profile: Maulikkumar Patel, Cyril Pottier

Förderung

  • Association for Frontotemporal Degeneration

Zitieren

APA

Patel, M., Kumar, P., Western, D., Johnson, M., Liu, M., Budde, J., Cruchaga, C., & Pottier, C. (2026). The shared genetic architecture of the TDP‐43 spectrum: Bridging clinical FTLD and neuropathological endophenotypes. Alzheimer's & Dementia, 22(11). https://doi.org/10.1002/alz.71943

Vancouver

Patel M, Kumar P, Western D, Johnson M, Liu M, Budde J, et al. The shared genetic architecture of the TDP‐43 spectrum: Bridging clinical FTLD and neuropathological endophenotypes. Alzheimer's & Dementia. 2026;22(11). doi:10.1002/alz.71943

BibTeX
@article{Patel2026,
  author = {Patel, Maulikkumar and Kumar, Pawan and Western, Daniel and Johnson, Matthew and Liu, Menghan and Budde, John and Cruchaga, Carlos and Pottier, Cyril},
  title = {The shared genetic architecture of the TDP‐43 spectrum: Bridging clinical FTLD and neuropathological endophenotypes},
  journal = {Alzheimer's & Dementia},
  year = {2026},
  volume = {22},
  number = {11},
  doi = {10.1002/alz.71943}
}
Kostenlos starten →